Immune regulatory mechanisms of PD-1 and advances in tumor immunotherapy research

<?A3B2 tlsb=.01w?>Programmed cell death protein 1 (PD-1) has emerged as a pivotal immunoregulatory molecule, whose influence extends far beyond its conventional role in inhibiting T cell activation. Recent groundbreaking research has uncovered its critical involvement in modulating the functions of various immune cell subsets, including macrophages and natural killer (NK) cells, and surprisingly, its direct expression and functional significance within tumor cells themselves. This comprehensive review aims to systematically elucidate the multifaceted regulatory mechanisms of PD-1 <?A3B2 pi129?>across diverse immune cell populations and critically examine the intriguing phenomenon of intrinsic PD-1 <?A3B2 pi129?>expression in tumor cells. We delve into how this tumor-intrinsic PD-1 <?A3B2 pi129?>can exert dual regulatory effects—either promoting or suppressing tumorigenesis—via non-immune pathways, such as influencing tumor stem cell properties, cellular proliferation, and apoptosis. Despite the transformative impact of PD-1/PD-L1 inhibitors in cancer therapy, their efficacy varies significantly across different tumor types, highlighting the complex interplay within the tumor microenvironment and the emergence of resistance mechanisms. This review synthesizes current understanding of these differential therapeutic outcomes and addresses key challenges, including primary and acquired resistance, and the risk of hyperprogressive disease (HPD). We discuss various resistance mechanisms, such as antigen presentation defects, the formation of suppressive tumor microenvironments, the activation of alternative immune checkpoints, and oncogenic pathway abnormalities. Furthermore, we explore innovative strategies to overcome these limitations, including combination therapies involving PD-1 <?A3B2 pi129?>antibodies with anti-angiogenic drugs, LAG-3 inhibitors, or bispecific antibodies targeting PD-1/VEGF, which hold immense promise in enhancing anti-tumor immunity and combating resistance. The review also highlights emerging research directions, particularly targeting tumor-intrinsic PD-1 with small molecule inhibitors to inhibit tumor stemness and proliferation via downstream signaling pathways. We emphasize the potential of multi-modal approaches combining PD-1 <?A3B2 pi129?>antibodies with small molecule inhibitors or mTOR pathway inhibitors to synergistically modulate both tumor cells and the immune microenvironment. Moving forward, a deeper understanding of the PD-1 <?A3B2 pi129?>signaling networks within specific cancer types and cell subtypes is crucial. We propose that future research should focus on deciphering these intricate networks to develop highly specific targeted therapies and combination regimens, coupled with the establishment of predictive biomarker systems. This approach will be instrumental in advancing tumor immunotherapy towards more broad-spectrum, efficient, and precise clinical applications, ultimately benefiting a wider patient population by overcoming current therapeutic hurdles and fostering sustained anti-tumor responses. <alternatives id="alt2"> </alternatives>